Mizuho lowered the firm’s price target on Cooper Companies (COO) to $105 from $120 and keeps an Outperform rating on the shares as part of a Q1 preview for the medical devices and diagnostics group. The firm views tariffs, China exposure, and the latest procedure outlook as the key themes heading into the quarter. It cut numbers preemptively.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COO:
- Cooper Co: Strategic Positioning and Market Dynamics Present a Compelling Buy Opportunity
- Morgan Stanley says Planned Parenthood cuts likely immaterial for Cooper
- Hold Rating for Cooper Co Amid Minimal Impact from Planned Parenthood Funding Cuts
- Cooper Companies management to meet with Piper Sandler
- Cooper Co: A Compelling Buy Amid Market Uncertainties and Attractive Valuation